Key facts
- Notable investors include Hankang Capital, Deep Intelligent Pharma, Everest VC, Longmen Capital, Shanghai Genesis International Equity Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Jinkebo Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Jinkebo Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jinkebo Biotechnology
Manufacturer of a gene therapy research and production system designed to support the development and preclinical advancement of genetic medicines. The company offers viral vector construction and optimisation, scalable cell culture and virus production workflows, quality control frameworks, and preclinical validation capabilities, enabling biotechnology and clinical research organizations to advance gene therapy candidates with consistency and scientific rigour.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Jinkebo Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jinkebo Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jinkebo Biotechnology in its N-PORT filings yet. We sweep new filings monthly.